Universal Ibogaine Inc. (IBO.V)

CAD 0.03

(0.0%)

Total Debt Summary of Universal Ibogaine Inc.

  • Universal Ibogaine Inc.'s latest annual total debt in 2022 was 1.73 Million CAD , up 323.82% from previous year.
  • Universal Ibogaine Inc.'s latest quarterly total debt in 2023 Q3 was 2.65 Million CAD , up 16.24% from previous quarter.
  • Universal Ibogaine Inc. reported annual total debt of 410 Thousand CAD in 2021, down 0.0% from previous year.
  • Universal Ibogaine Inc. reported annual total debt of - CAD in 2020, down 0.0% from previous year.
  • Universal Ibogaine Inc. reported quarterly total debt of 2.28 Million CAD for 2023 Q2, down -0.77% from previous quarter.
  • Universal Ibogaine Inc. reported quarterly total debt of 2.29 Million CAD for 2023 Q1, up 32.3% from previous quarter.

Annual Total Debt Chart of Universal Ibogaine Inc. (2022 - 2017)

Historical Annual Total Debt of Universal Ibogaine Inc. (2022 - 2017)

Year Total Debt Total Debt Growth
2022 1.73 Million CAD 323.82%
2021 410 Thousand CAD 0.0%
2020 - CAD 0.0%
2019 - CAD 0.0%
2018 - CAD 0.0%
2017 - CAD 0.0%

Peer Total Debt Comparison of Universal Ibogaine Inc.

Name Total Debt Total Debt Difference
Arch Biopartners Inc. 5.01 Million CAD 65.359%
Covalon Technologies Ltd. 1.56 Million CAD -11.214%
Hemostemix Inc. 4.32 Million CAD 59.79%
Kane Biotech Inc. 8.27 Million CAD 79.003%
MedMira Inc. 9.27 Million CAD 81.257%
Marvel Biosciences Corp. 1 Million CAD -73.767%
NervGen Pharma Corp. 197.19 Thousand CAD -781.218%
XORTX Therapeutics Inc. 15.17 Thousand CAD -11349.384%